Endo Pharmaceuticals has partnered with Jubilant Organosys, a Bangalore-based pharma manufacturer, for the potential development of oncology preclinical candidates. Terms of the collaboration include Endo ownership and worldwide commercialization rights on any compounds developed. Under the three-year agreement, Jubilant will receive research funds from Endo, as well as success-based milestones and royalty payments should any of the compounds come to fruition.
Top pharma brass – John Lechleiter, CEO at Lilly and Adam Schechter, president of global pharmaceuticals at Merck – made separate statements on Wednesday opposing a government-run healthcare offering that would compete with private insurers, Reuters reported. “You’d have 100 million people shuttled in overnight; it would limit coverage and delay access,” said Lechleiter. The statements were made at the Goldman Sachs Annual Healthcare Conference in New York.
